Bavarian Nordic GmbH

Founded in 1994, Bavarian Nordic A/S is a leading international biopharmaceutical company developing, producing and marketing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany and the USA, Bavarian Nordic employs more than 220 people and is listed on the Copenhagen Stock Exchange. Bavarian Nordic's patented core technology MVA-BN® is one of the world´s safest, multivalent vaccine vectors and is ideally suited for use against various infectious diseases such as HIV/AIDS and smallpox as well as cancer.